Abstract
Research has recently focused on combinational therapy using nanocarriers to overcome the obstacles associated with conventional therapy of lung cancer. The classical therapeutic approach is indeed insufficient for suppressing tumor growth. Simultaneous delivery improves therapeutic outcomes, synergistic effects, and targeting moiety. Besides, multidrug-loaded nanocarriers allows the consecutive release of two or more drugs and genes. A such nanodrug delivery system reduces drug–drug interactions and improves the pharmacokinetics profile of loaded drugs. Currently, nanotechnology-based co-delivery system is the only suitable option for lung cancer therapy. Combinational delivery systems show promising results for the treatment of lung cancer. Here we review the design and development of co-delivery systems based on nanocarriers for effective cancer treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
